<DOC>
	<DOC>NCT02724345</DOC>
	<brief_summary>To evaluate and analyse the clinical effect and application value of postoperative adjuvant TACE treatment in patients with different expression levels of CK18 using randomized controlled study and provide evidence for the necessity of postoperative adjuvant TACE.</brief_summary>
	<brief_title>Postoperative Adjuvant TACE Treatment in CK18 Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>1. Via clinical diagnosis and confirm it is primary liver cancer 2. Pathological evidence of HCC 3. Estimate tumor can gain treatment of curing operation 4. No evidence for extrahepatic metestasis 5. liver function ：ChildPugh A/B 1. reject to attend； 2. impossible to come to our hospital for physical examination regularly. 3. cancer epitome、seed focus、lymph node or distant metastasis 4. Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cell keratin 18</keyword>
</DOC>